For personal use only

SUDA LTD

ACN 090 987 250

ASX Release

SUDA ANNOUNCES PEER-REVIEWED CLINICAL PUBLICATION OF ARTIMIST™ IN SCIENTIFIC JOURNAL

PERTH, AUSTRALIA – 27 August 2015: SUDA LTD (ASX: SUD), a leader in oro-mucosal drug delivery, today announces that a third peer-reviewed article describing ArTiMist™ clinical data has been published in Antimicrobial Agents and Chemotherapy (AAC), which is a journal of the American Society for Microbiology. The AAC is one of the most respected peer-reviewed scientific journals for preclinical and clinical data on novel anti-malarial treatments.

The article, which is titled, '***Efficacy of a novel sublingual spray formulation of artemether in African children with falciparum malaria'***, sets out the results from SUDA's two clinical efficacy studies of ArTiMist™ including the Phase III trial in children with severe, complicated or uncomplicated malaria, but who were unable to tolerate oral medication.

In both studies, the efficacy of sublingual ArTiMist™ was compared to the standard-of-care intravenous (iv) quinine. There were 31 children in the Phase II study and 151 children in the Phase III trial. Patients were randomised to receive either ArTiMist™ or iv quinine. The primary endpoint was parasitological success, defined as a reduction in parasite count of ≥ 90 % of baseline at 24 hours after the first dose. In the Phase II study, there was 93% parasitological success with ArTiMist™ versus 67% for iv quinine. In the Phase III study, 94% of ArTiMist™-treated patients compared to 39% of patients treated with iv quinine had parasitological success ($p < 0.0001$). Indicators of parasite clearance were also significantly superior for children treated with ArTiMist™ than those treated with iv quinine.

SUDA's CEO, Mr Stephen Carter, commented: "We are delighted to have a third manuscript published in the prestigious AAC journal. It confirms the importance of the clinical data and the high level of interest in ArTiMist™ amongst the scientific community in the field of malaria. The results from the two clinical efficacy studies clearly demonstrate that treatment with ArTiMist™ leads to superior parasite clearance and clinical recovery compared to intravenous quinine. We are working with our advisers as well as groups such as the Medicines for Malaria Venture to bring ArTiMist™ to the market at the earliest opportunity. This publication provides further endorsement of the product and supports our strategy for registration and partnering."

For personal use only

Further information:
STEPHEN CARTER
CHIEF EXECUTIVE OFFICER / MANAGING DIRECTOR
SUDA LTD
Tel: +61 8 6142 5555
sjcarter@sudaltd.com.au

NOTES TO EDITORS:

About SUDA LTD

SUDA LTD (ASX: SUD) is a drug delivery company focused on oro-mucosal administration, headquartered in Perth, Western Australia. The Company is developing novel oral spray formulations of existing off-patent pharmaceuticals using its proprietary OroMist® drug delivery technology platform. The many potential benefits of administering drugs through the oral mucosa (ie: cheeks, tongue, gums and palate) include ease of use, lower dosage, reduced side effects and faster response time. SUDA's product pipeline includes ZolpiMist®, a first-in-class oral spray of zolpidem for insomnia. ZolpiMist® has been approved in the USA and SUDA has rights to the product outside of the Americas and South Africa. SUDA's most advanced development-stage product, ArTiMist™, is a novel sublingual malaria treatment for children. In a Phase III trial, ArTiMist™ was shown to be superior to intravenous quinine. Other products in development include oral sprays for the treatment of migraine headache, chemotherapy-induced nausea and vomiting, erectile dysfunction and pre-procedural anxiety. For more information, visit www.sudaltd.com.au

About ArTiMist™

ArTiMist™ was designed with a child in mind; a child living in a challenging environment where healthcare resources can be very scarce and time is of the essence. ArTiMist™ is the world's first sub-lingual spray for the treatment of *p. falciparum* paediatric malaria. The active pharmaceutical ingredient in ArTiMist™ is artemether, which is a widely used anti-malarial and is currently administered by infusion or orally in a tablet form. ArTiMist™ is administered sublingually or under the tongue and enters the bloodstream where the parasite lives, attacking at a far greater speed than conventional tablets and reducing the need for continued hospitalisation whilst presenting significant cost savings to governments and relief organisations. ArTiMist™ could be particularly valuable as a pre-referral treatment of sick children before they are transferred to hospitals for definitive management of severe or moderately severe malaria.